How PCV2 vaccines work
Despite not having a consistent post-vaccination serological reaction, vaccinated animals behave differently from unvaccinated animals under field conditions.The article explains why vaccines offer protection.
Page 12 of articles about vaccine
Live attenuated African swine fever viruses as ideal tools to dissect the mechanisms involved in viral pathogenesis and immune protection
The findings will be of utility for a better understanding of ASFV pathogenesis and for the rational designing of safe and efficient vaccines against this virus.
Post-weaning E. coli immunity
In practice, and to have active-acquired antibodies ready at weaning, piglets should be immunised 10 days to 2 weeks before weaning.
Effect of vaccination against PRRSV on virus shedding
Effect of modified-live porcine reproductive and respiratory syndrome virus vaccine on the shedding of wild-type virus from an infected population of growing pigs.
European Union: Progress on two proposals considered as a package on "Animal medicines"
The Presidency reported to the Agriculture and Fisheries Council on the progress achieved during the second half of 2015 on two proposals considered as a package on 'Animal medicines'.
Use of a live attenuated Salmonella enterica serovar Typhimurium vaccine
These findings indicate that vaccination with an attenuated S. Typhimurium strain reduces S. enterica shedding, but the reduction is not consistent and the vaccine strain may persist in tissues.
Efficacy of a live attenuated vaccine in classical swine fever virus postnatally persistently infected pigs
To our knowledge, this is the first report demonstrating the absence of a response to vaccination in CSFV persistently infected pigs.
Stochastic model of PRRSV control strategies on a swine farm in the United States
After 24 years of experience we still don't have a control plan agreed upon and accepted by all our technical community. Why?
Oral vaccine platform based on the yeast Saccharomyces cerevisiae to combat PCV2
The results presented here demonstrate a possible use for recombinant S. cerevisiae expressing viral proteins as an oral vaccine against PCV2.
Efficacy of combined vaccination against Mycoplasma hyopneumoniae and porcine reproductive and respiratory syndrome virus in dually infected pigs
In conclusion, combined vaccination against both Mhp and PRRSV efficiently pooled the efficacy of each single PRRSV and Mhp vaccination and could be an interesting tool to control PRDC in European swine production.
A two-year follow-up study of the PCV2 status of a Danish pig herd that was initially assumed to be PCV2-free
The results from this herd indicated that PCV2 vaccination may reduce the PCV2 infection level even during an acute outbreak of PRRS, but the results also showed that PCV2 vaccination does not eradicate the virus from the herd. Further studies are needed to draw general conclusions on this matter.
Ceva enters European swine vaccine market with new, targeted vaccine to improve control of enzootic pneumonia
Experts meet in Barcelona to discuss new strategies to prevent the disease.
Boehringer Ingelheim Animal Health launches two new swine vaccines in Europe
New vaccines Ingelvac PRRSFLEX® EU for piglets and ReproCyc® PRRS EU for sows offer sustainable control of Porcine Reproductive and Respiratory Syndrome (PRRS).
Which is the best age for piglet PCV2 vaccination?
This article deals with the factors to be considered for deciding the optimal time of vaccination against PCV2 and shows the results of a study that evaluates the efficacy of different vaccination programs in PCV2 subclinically infected piglets.
Control of reproductive PRRS outbreak by type 1 PRRS vaccine
In Korea, it is common to vaccinate sows as a whole-herd mass vaccination program, where all sows are vaccinated quarterly with a type 2 PRRSV vaccine. Therefore, it is recommended to vaccinate breeding females quarterly with additional type 1 PRRSV vaccine to control type 1 PRRSV infection.
Vaccination of pigs reduces Torque teno sus virus viremia during natural infection
This study demonstrated for the first time that TTSuV viremia can be controlled by a combined DNA and protein immunization.